European public procurement and grants data from official registers · Data as of 18 November 2026; updated daily.

Tenders

Oncology drug tenders in France

Oncology drug tenders in France: 154 listed on GranTender since 2024; none is open now. The median awarded contract value is about €330,000 (174 contracts with a stated value). Buyers with the most tenders: CHU Rouen Normandie (11), Centre Hospitalier Universitaire de Nantes (8) and APHP Sorbonne Université (5); suppliers with the most contract awards: Teva Sante (28), Arrow Generiques (27) and PFIZER (26). Sources: DECP, BOAMP and TED. In 2025, 5% of contracts drew a single bid (16.9 bids on average). Data as of 18 November 2026; updated daily.

Tenders
154
Open tenders
0
Awards
502
Awarded value awarded
€1,901,379,929
Awarded value contract
€1,190,853,563
Awarded value framework ceiling
€1,901,379,929
Median contract value awarded
≈ €330,000
Median contract value framework ceiling
≈ €330,000
Median contract value contract
≈ €330,000
Average bids per contract
51.0
Tenders in 2025
24 -79% on 2024

Median: contracts with a stated value, rounded. Average bids: contracts where the number of bids is published.

Value kinds: awarded — the value in the award decision; contract — the value of the signed or amended contract; paid — the amount actually paid; framework ceiling — the maximum of a framework agreement, given with every winner, not money spent. Different kinds are never added together.

Open tenders

No records yet.

Latest tenders

TenderBuyerEstimated valueStatusPublished
Fourniture des traitements nécessaires à l'étude OPTIVASCHRU de Tours—Awarded1 June 2026
La présente consultation a pour objet la fourniture de Rituximab.Centre Hospitalier Universitaire de Nantes—Awarded10 June 2025
Fourniture de RITUXIMAB pour le GHT 44 (1 lot)Centre Hospitalier Universitaire de Nantes—Awarded3 April 2025
AO MEDICAMENTS ANTINEOPLASIQUES ET IMMUNOMODULATEURS (Classe ATC L) - Relance de 4 lotsCH de Saint-Brieuc/Paimpol/Tréguier - Etablissement support du GHT d'ARMOR€41,000,000Awarded24 July 2024
Lot 120 IMM24 Anticancéreux : Epoetine biosimilaire toutes indications.GCS UniHA—Awarded1 June 2024
Fourniture de médicaments cytotoxiques pour le GHT 44 - La présente consultation comporte 28 lotsCentre Hospitalier Universitaire de Nantes—Awarded2 May 2024
Fourniture de médicaments cytotoxiques pour le GHT 44 - La présente consultation comporte 28 lotsCentre Hospitalier Universitaire de Nantes—Awarded30 April 2024
Fourniture de médicaments cytotoxiques pour le GHT 44 - La présente consultation comporte 28 lotsCentre Hospitalier Universitaire de Nantes—Awarded30 April 2024
FOURNITURE DE MEDICAMENTS BIOSIMILAIRES ET GENERIQUES (12 LOTS)Centre Hospitalier Universitaire de Nantes—Closed7 February 2024
Fourniture de MEDICAMENTS ANTICANCEREUX, HORMONOTHERAPIE, ET THERAPIES ASSOCIEES, et des prestations associéesAPHP Sorbonne Université€100,000,000Closed30 January 2024
France-Nantes: ImmunosuppresseursCentre Hospitalier Universitaire de Nantes—Closed9 January 2024
FOURNITURE DE MEDICAMENTS BIOSIMILAIRES ET GENERIQUES (12 LOTS)Centre Hospitalier Universitaire de Nantes€14,894,748Closed6 January 2024

Competition and prices

In 2025, contracts drew 16.9 bids on average (median 22) and 5% drew a single bid — based on 38 contracts with a known number of bids. Compared with 2024, in 2025 the share of single-bid contracts rose from 4% to 5%.

The most contracts went to Teva Sante (28), Arrow Generiques (27) and PFIZER (26) — together 16% of all contracts.

YearContractsMedian valueMiddle half of valuesBids on averageSingle bid
2024448€370,000€73,000 – €3.7 million54.24% (445)
202540——16.95% (38)
All years502€330,000€82,000 – €3.1 million51.04% (486)

Values: contracts with a stated value in EUR, each value kind on its own (awarded or contract value), approximate (±3 %). Bids: contracts of procedures with competition whose number of bids the source publishes (1–100 bids); the sources publish it for some contracts only (TED ≈ 3 in 4, Spain all, Poland about half, Italy few), so each figure states its base and is shown from 20 contracts. A contract counts in the year of its award (else of its tender). Figures as of 13 November 2026, recomputed every week.

Where you have a chance

Since 1 November 2024, 10% of the 41 contracts with a known number of bids had a single bid; the median was 7 bids. The number of bids is known for 41 of the 55 contracts from procedures with competition.

Contracts awarded since 1 November 2024 (the last 24 months). Bids as the source publishes them, 1 to 100 per contract, in procedures with competition only (a direct award has one offer by design). As of 13 November 2026.

Main CPV divisions

CPV codes of this topic

  • 33652000 Antineoplastic and immunomodulating agents

A tender belongs here when its main CPV code starts with one of these codes; a tender without a usable CPV code (or with a general one) is matched by words of its title. A tender may belong to up to three topics.

Oncology and immunomodulating drugs in neighbouring countries

Today, 2 tenders in the same niche are open in neighbouring countries.

Public tenders in the EU and the EEA are open to companies from every EU and EEA country on the same terms as local ones, and to companies from countries with a procurement agreement with the EU (such as Switzerland, the United Kingdom and Ukraine) for the contracts it covers. Open means the deadline has not passed (today's date). Neighbours: countries with a land border, a fixed link or a short sea crossing.

Expected soon2

ExpectedBuyerWhatWhy we expect itConfidence
Dec 2026 – May 2027
contract ends
GCS UniHAOncology and immunomodulating drugs
Lot 120 IMM24 Anticancéreux : Epoetine biosimilaire toutes indications.
Typical value: ≈ €120,000
The current contract with PFIZER ends on 1 June 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 06/2024
medium
Dec 2026 – May 2027
contract ends
Centre Hospitalier Universitaire de NantesOncology and immunomodulating drugs
La présente consultation a pour objet la fourniture de Rituximab.
Typical value: ≈ €3.8m
The current contract with SANDOZ ends on 10 June 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 06/2025
high

Forecast from public data, not an announcement. Methodology.

Market reports

Oncology and immunomodulating drugs by city

Oncology and immunomodulating drugs in other countries

Oncology and immunomodulating drugs across Europe

Topics in Health, medical equipment and medicines

Questions and answers

Which oncology drug tenders in France are open now?
None is open at the moment; GranTender lists 154 in total.
Where can I find oncology drug tenders in France?
GranTender lists them in one place, from DECP, BOAMP and TED, with their buyers, winners and contract values; 0 are open now. Search in one country at a time (the first 5 results) is free; search across all countries at once, full result lists, saved keywords with an e-mail once a week and exports come with a plan.
Who wins the most oncology drug tenders in France?
By number of contracts won: Teva Sante (28), Arrow Generiques (27), PFIZER (26).
Which buyers publish the most oncology drug tenders in France?
By number of tenders: CHU Rouen Normandie (11), Centre Hospitalier Universitaire de Nantes (8), APHP Sorbonne Université (5).
What is a typical contract value for oncology drug tenders in France?
The median contract value is about €330,000 (awarded value, 174 contracts with a stated value).
Which CPV codes belong to “Oncology and immunomodulating drugs”?
33652000 Antineoplastic and immunomodulating agents; plus tenders without a usable CPV code whose title names the topic.
How many bids do oncology drug tenders in France receive on average?
In 2025, contracts drew 16.9 bids on average (median 22) and 5% drew a single bid — based on 38 contracts with a known number of bids.

CPV 2008 (Regulation (EC) No 213/2008), © European Union, Publications Office — via the eForms SDK, CC BY 4.0.